Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression–Severity of Suicidality–revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change. Results: Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: –15.7 [11.56]) vs placebo (–12.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: –3.9 [1.39], 95% CI: –6.60, –1.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference –4.2, 95% CI: –6.38, –1.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression–Severity of Suicidality–revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia. Conclusion: This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least-square mean changes (±SE) from baseline for Montgomery-Asberg Depression Rating Scale (MADRS) total score during the double-blind treatment phase (mixed-effects model using repeated measures [MMRM]; observed cases). aIncludes patients who had their dose reduced due to tolerability issues. Note: Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/867338dabcaf42aca05b1ca83661094a/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317 · cited 1×
“Nearly all patients with MDD who attempt or complete suicide have suicidal ideation prior to the event (Brown et al., 2000; Sokero et al., 2003).”
BackgroundValidity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“Eligible patients were between 18 and 64 years of age, met the Diagnostic and Statistical Manual of Mental Disorders–5th edition (DSM-5) criteria (American Psychiatric Association, 2013) for MDD (without psychosis) based on diagnostic assessment with the Mini International Neuropsychiatric Interview, and had a MADRS (…”
MethodPractice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.56008 · Cited by 406
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390 · cited 3×
“Current standard of care includes initiation or optimization of oral antidepressants and, frequently, hospitalization (American Psychiatric Association, 2003; Wasserman et al., 2012).”
Background
Research works printed but not linked: 1
- Spravato (esketamine) nasal spray. Prescribing information. 2020. Janssen Pharmaceutical Companies.
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationOvercoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 172
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“A recent study evaluated the efficacy of esketamine nasal spray (84 mg) administered twice a week versus placebo for four weeks in MDD patients with suicidal ideation in conjunction with standard care [43].”
BackgroundNew and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 137
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“This discovery led to the approval of a nasal spray form of esketamine that is supposed to provide relief in patients with TRD [18].”
BackgroundLong-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Canuso, C. M., Ionescu, D. F., Li, X., Qiu, X., Lane, R., Turkoz, I., Nash, A. I., Lopena, T. J., & Fu, D.-J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001465 · Cited by 88
Self-citationEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Self-citationEsketamine for Treatment-Resistant Depression: A Review of Clinical Evidence (Review)
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11810 · Cited by 82
“%) were dizziness, dissociation, nausea, drowsiness and headache (31,32,34).”
InfluentialYan, H., Chen, W., Chen, Y., Gao, H., Fan, Y., Feng, M., Wang, X., Tang, H., Yin, J., Qian, Y., et al. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006547 · Cited by 99
Bahji, A., Zarate, C. A., & Vazquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 73
Novel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 89
Nikkheslat, N. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 71
Siegel, A. N., Di Vincenzo, J. D., Brietzke, E., Gill, H., Rodrigues, N. B., Lui, L. M. W., Teopiz, K. M., Ng, J., Ho, R., McIntyre, R. S., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.009 · Cited by 70
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Psychiatry in the Digital Age: A Blessing or a Curse?
Roth, C. B., Papassotiropoulos, A., Brühl, A. B., Lang, U. E., & Huber, C. G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168302 · Cited by 83
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 71
Self-citationAccelerated intermittent theta burst stimulation in major depressive disorder: A systematic review
Neuteboom, D., Zantvoord, J. B., Goya‐Maldonado, R., Wilkening, J., Dols, A., van Exel, E. R., Lok, A., de Haan, L., & Scheepstra, K. W. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115429 · Cited by 70
“A pilot study in 2021 found that a higher number of pulses of rTMS in 29 MDD patients enhanced reduction in depressive symptoms (Johansson et al., 2021).”
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
McQuaid, J. R., Buelt, A., Capaldi, V., Fuller, M., Issa, F., Lang, A. E., Hoge, C., Oslin, D. W., Sall, J., Wiechers, I. R., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1603 · Cited by 59
“However, the effectiveness of esketamine in preventing suicide or reducing suicidal ideation or behavior has not been established (35, 36).”
Backgroundd’Andrea, G., Pettorruso, M., Lorenzo, G. D., Rhee, T. G., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., Nicola, M. D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.038 · Cited by 60
Prescriber's Guide: Stahl's Essential Psychopharmacology
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 87
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
“Four [15,16,20,21] studies used flexible doses while other four [17,19,29,30] used fixed doses of intranasal esketamine.”
BackgroundInfluentialFeeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 64
Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., Tu, P., Chen, L., Li, W., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad014 · Cited by 66
“Finally, the inpatient setting was conducted in previous esketamine or ketamine clinical trials of patients with major depressive disorder and suicidal thoughts (Murrough et al., 2015; Grunebaum et al., 2018; Fu et al., 2020; Ionescu et al., 2021).”
Reporting of harms in clinical trials of esketamine in depression: a systematic review
de Laportalière, T. T., Jullien, A., Yrondi, A., Cestac, P., & Montastruc, F. (2023) · Psychological Medicine · doi:10.1017/s0033291723001058 · Cited by 58
“1) (Canuso et al., 2018; Daly et al., 2018, 2019; Fedgchin et al., 2019; Fu et al., 2020; Ionescu et al., 2021; Table 1.”
Research advances in the clinical application of esketamine
Zhang, X., Zhang, N., Liu, D., Ding, J., Zhang, Y., & Zhu, Z. (2022) · Ibrain · doi:10.1002/ibra.12019 · Cited by 47
“For patients with major depression who have active suicidal ideation, compared with the specific delayed onset characteristics of traditional oral antidepressants, the use of esketamine nasal spray can quickly and effectively relieve the symptoms of depression.(30) Patients over 65 years of age with refractory depress…”
MethodSafety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review
Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2707 · Cited by 50
Psiuk, D., Nowak, E., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911450 · Cited by 54
Inpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
Self-citationFeeney, A., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B. B., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.024 · Cited by 42
Self-citationThe therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Jawad, M. Y., Vincenzo, J. D. D., Badulescu, S., Teopiz, K. M., Tabassum, A., Ceban, F., Mckenzie, A., Meshkat, S., Rosenblat, J. D., Ho, R., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109299 · Cited by 36
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
Chen, C., Zhou, N., Hu, N., Feng, J., & Wang, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s401032 · Cited by 39
Vieira, F., Correia‐Melo, F. S., Santos‐Lima, C., Souza‐Marques, B., Leal, G. C.-G., Jesus‐Nunes, A. P., Mello, R. P., Caliman‐Fontes, A. T., Bandeira, I. D., Marback, R. F., et al. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.12.011 · Cited by 34
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 34
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Sadeghi, H. M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. R. (2021) · Life · doi:10.3390/life11080774 · Cited by 31
Capuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179338 · Cited by 41
Jawad, M. Y., Vincenzo, J. D. D., Ceban, F., Jaberi, S., Lui, L. M. W., Gillissie, E. S., Alnefeesi, Y., Rosenblat, J. D., & McIntyre, R. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2058488 · Cited by 37
Boudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
“…study, the decrease in MADRS scores between baseline and 24 h after the first administration (LS mean difference [SE]: − 3.9 [1.39], p = 0.006) and day 25 pre-dose (LS mean difference: –3.7, 95% CI: –7.09; –0.38) was significantly greater in the IN esketamine group compared to the placebo group [31].”
BackgroundMethodResultInfluentialKato, M., Nakagome, K., Baba, T., Sonoyama, T., Okutsu, D., Yamanaka, H., Shimizu, R., Motomiya, T., & Inoue, T. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13569 · Cited by 32
“006 for both, respectively) and thereafter over the 4-week double-blind treatment.(36,37) Although a direct comparison cannot be made, the improvement in the zuranolone 20- and 30-mg groups vs the placebo group was similar to that achieved with rapid-acting agents that exert their effects via modulation of glutamate/G…”
ResultLengvenytė, A., Olié, É., Strumila, R., Navickas, A., González-Pinto, A. M., & Courtet, P. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1907712 · Cited by 26
“Only six studies justified their sample size by performing power calculations to detect meaningful differences in SI (Yovell et al. 2016; Grunebaum et al. 2018; Diamond et al. 2019; McCall et al. 2019; Fu et al. 2020; Ionescu et al. 2020), and one study performed power calculations to detect differences in SA within s…”
BackgroundInfluentialSymptomatic versus disease‐modifying effects of psychiatric drugs
Ghaemi, S. N. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13459 · Cited by 30
“Suicidality is not markedly reduced, but only modestly based so in the largest recent studies.(22) Such benefit in suicidal ideation, however limited, has not been shown to translate into prevention of completed suicide or decreased mortality.”
BackgroundHalaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 32
Colla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.002 · Cited by 23
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 24
“Full inclusion and exclusion criteria have been previously published [16, 17].”
BackgroundMethodInfluentialSelf-citationIngrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 28
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Overcoming the myths of esketamine administration: different and not difficult
Buchmayer, F., & Kasper, S. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1279657 · Cited by 25
Self-citationNicola, M. D., Pepe, M., d’Andrea, G., Marcelli, I., Pettorruso, M., Andriola, I., Barlati, S., Carminati, M., Cattaneo, C. I., Clerici, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15040161 · Cited by 24
“…high-baseline suicidality has been associated with a reduced likelihood of response to ESK-NS at one and three months of treatment [14], glutamatergic antagonists, including intravenous ketamine and ESK-NS, have been shown to reduce suicide ideation and prevent suicidal behavior in TRD [20,32–35].”
Gonda, X., Döme, P., Serafini, G., & Pompili, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108390 · Cited by 22
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Yi, Z., Xia, L., Yi, J., Jia, Y., Wei, L., Shen, S., Wu, N., Wang, D., Zhou, H., Li, X., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291724003283 · Cited by 21
Kosik‐Gonzalez, C., Fu, D., Chen, L. N., Lane, R., Bloch, M. H., DelBello, M. P., Moreno, C., Drevets, W. C., & Canuso, C. M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1016/j.jaac.2025.02.015 · Cited by 26
Self-citationMatsingos, A., Wilhelm, M., Noor, L., Yildiz, C., Rief, W., Hofmann, S. G., Falkenberg, I., & Kircher, T. T. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1346697 · Cited by 27
Ju, M., Zhang, Z., Gao, F., Chen, G., Zhao, S., Wang, D., Wang, H., Jia, Y., Shen, L., Yuan, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402219 · Cited by 21
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 23
“The adverse events profile was similar to the first trial, with the addition of dysgeusia and paresthesia amongst the common complaints for those who received esketamine [72].”
Hecking, J., Davoudian, P. A., & Wilkinson, S. T. (2021) · Chronic Stress · doi:10.1177/24705470211020446 · Cited by 20
“30, respectively).(17,18,40) AVP-786 AVP is an oral formulation that combined dextromethorphan and quinidine.”
BackgroundVanicek, T., Unterholzner, J., Lanzenberger, R. R., Naderi‐Heiden, A., Kasper, S. F., & Praschak-Rieder, N. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2031287 · Cited by 19
“This has also been shown with intranasal (i.n.) application of esketamine (Ionescu et al. 2021).”
BackgroundSelf-citationBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Oraee, S., Alinejadfard, M., Golsorkh, H., Sadeghian, M., Fanaei, M., Centis, R., D’Ambrosio, L., Sotgiu, G., Goudarzi, H., Migliori, G. B., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.010 · Cited by 22
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s314874 · Cited by 18
Self-citationCraving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
Williamson, D. J., Gogate, J. P., Sliwa, J. K. K., Manera, L. S., Preskorn, S. H., Winokur, A., Starr, H. L., & Daly, E. J. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14318 · Cited by 15
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
Song, H., Luo, Y., & Fang, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s486118 · Cited by 21
“53,55 Esketamine causes less cognitive impairment, reduced attention, and memory loss than ketamine, so esketamine is safer and better tolerated than ketamine.”
BackgroundBlinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 22
Determining maximal achievable effect sizes of antidepressant therapies in placebo‐controlled trials
Hieronymus, F., Lisinski, A., Hieronymus, M., Näslund, J., Eriksson, E., & Østergaard, S. D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13340 · Cited by 14
Wilkowska, A., & Cubała, W. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1322752 · Cited by 20
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 28
“Moreover, researchers employed a key secondary endpoint by measuring the Clinical Global Impression of Severity of Suicidality-revised (CGISS-r) score, which saw rapid reductions in both ASPIRE I and II [17,18].”
BackgroundMethodResultInfluentialStress, mental disorder and ketamine as a novel, rapid acting treatment
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.006 · Cited by 18
Chen, B. K., Pen, G. L., Eckmier, A., Rubinstenn, G., Jay, T. M., & Denny, C. A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab007 · Cited by 14
“…for reducing symptoms of depression, including suicidality (Daly et al., 2018, 2019; Fedgchin et al., 2019; Popova et al., 2019; Fu et al., 2020; Ionescu et al., 2020; Nijs et al., 2020; Perez-Ruixo et al., 2020; Saad et al., 2020; Wajs et al., 2020; ClinicalTrials.gov, NCT0260929, NCT02094378,…”
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Singh, B., Voort, J. L. V., Pazdernik, V., Frye, M. A., & Kung, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.262 · Cited by 23
Jamieson, C., Canuso, C. M., Ionescu, D. F., Lane, R., Qiu, X., Rozjabek, H., Molero, P., & Fu, D. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03451-9 · Cited by 18
“In both studies, esketamine nasal spray plus SOC was associated with a rapid reduction in depressive symptoms of MDD in patients with active suicidal ideation with intent at 24 h after the first dose compared with a matched placebo nasal spray plus SOC, as assessed by clinician-rated outcome measures [11, 12].”
BackgroundMethodResultInfluentialSelf-citationPsychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
“149,150 The limited availability of evidence-based pharmacological treatments for SI in individuals with MDD and bipolar disorder underscores the urgent need for innovative interventions.”
BackgroundBenefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 16
Liu, X., Wei, Z., Li, L., Li, J., Deng, Y., Liu, Y., Li, H., Peng, D., Wan, X., & Wu, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.002 · Cited by 16
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 18
Pompili, M., Sarli, G., Erbuto, D., Manfredi, G., & Comparelli, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000455 · Cited by 18
Singh, M. K., & Thase, M. E. (2025) · CNS Spectrums · doi:10.1017/s1092852925000094 · Cited by 16
“8,11,12 However, ketamine and esketamine are classified as controlled substances that can cause dissociation and cardiovascular side effects that warrant up to 2 hours ’ of monitoring, which limits their potential for widescale clinical use.”
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Zhdanava, M., Teeple, A., Pilon, D., Shah, A., Caron‐Lapointe, G., & Joshi, K. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2208993 · Cited by 14
“In this study patient ’ s mean age and sex ratio were comparable to those in the esketamine MDSI trials 18,30,31 ; a numerical decrease was observed in inpatient and emergency department visits and total healthcare costs 6 months following esketamine initiation, signaling a potential reduction in…”
ResultTherapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 13
“One study stated that the psychiatrist programmed the infusion pump (Ionescu et al. 2020).”
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“In this review, four systematic review and meta-analyses of intranasal esketamine [46–49], and six phase III trials [50–56] were included.”
Intranasal esketamine use in bipolar disorder: A case report
Skriptshak, C., & Reich, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.07.259 · Cited by 12
Yao, Z., & McCall, W. V. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00467-x · Cited by 16
“Two multicenter trials of esketamine in hospitalized patients with active suicidal intent compared with placebo (both groups received standard of care antidepressant with or without augmentation agent at investigators’ discretion) showed that esketamine improved Montgomery Åsberg Depression Rating Scale (MADRS) scores…”
Background
Metadata
- Authors
- Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M.
- Affiliations
- Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA
- Janssen Research & Development (United States) (US)
- Medical University of Vienna (AT)
- Corresponding author
- Ionescu, Dawn F
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-29
- Volume
- 24
- Issue
- 1
- Pages
- 22-31
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816667
- OpenAlex
- W3082490768
- Cited by
- 418
- References
- 28
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 41 · 2023: 49 · 2022: 43 · 2021: 31 · 2020: 161
- FWCI
- 42.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, nasal spray, major depressive disorder, rapid-acting antidepressants, depressive symptoms, suicidality, hospitalization, adverse events, dissociation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Nasal Sprays, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.